Related Experiment Video
Updated: Jul 27, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
A long-term study to maximise migraine relief with zolmitriptan
S J Tepper1, G A Donnan, A J Dowson
1The Polyclinic, Seattle, USA.
Current Medical Research and Opinion
|January 20, 2000
Summary
Zolmitriptan effectively treats migraine headaches. A 5 mg dose significantly improved pain-free rates, and most patients achieved relief with one or two doses, showing good tolerability.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Migraine is a common neurological disorder.
- Effective acute treatment options for migraine are crucial.
Purpose of the Study:
- To evaluate the efficacy and tolerability of zolmitriptan for migraine treatment.
- To assess different dosing strategies for zolmitriptan.
Main Methods:
- Part 1: Randomized, double-blind, placebo-controlled trial of 2.5 mg and 5 mg zolmitriptan.
- Part 2: Non-comparative, long-term evaluation of zolmitriptan use in real-world settings.
Main Results:
- 5 mg zolmitriptan showed a significantly higher pain-free response rate (36.0%) compared to placebo (25.5%) for all migraine intensities.
- In Part 2, over 88.8% of attacks achieved headache relief with one or two doses of zolmitriptan.
- Zolmitriptan was well-tolerated and provided consistent migraine relief.
Conclusions:
- A second 5 mg dose of zolmitriptan can maximize migraine relief for patients with a partial response to an initial 2.5 mg dose.
- Zolmitriptan is an effective and well-tolerated treatment for acute migraine attacks, with most patients requiring only one or two doses.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...